From: A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial
Chemotherapeutic agent
Dosage (mg/m2)
Treatment day
Cetuximab
250 *
1, 8
* 400 at first application
Irinotecan
180
1
Folinic Acid
400
5Fluorouracil (bolus)
5Fluorouracil (46 hours)
2400